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Breast cancer cells show overexpression of estrogen receptor
(ER) a relative to ERb compared to normal breast tissues. This
observation has lead to the hypothesis that ERb may modulate
the proliferative effect of ERa. This study investigated how
variable cellular expression ratios of the ERa and ERb modulate
the effects on cell proliferation induced by ERa or ERb agonists,
respectively. Using human osteosarcoma (U2OS) ERa or ERb
reporter cells, propyl-pyrazole-triol (PPT) was shown to be
a selective ERa and diarylpropionitrile (DPN) a preferential
ERb modulator. The effects of these selective estrogen receptor
modulators (SERMs) and of the model compound E2 on the
proliferation of T47D human breast cancer cells with tetracycline-
dependent expression of ERb (T47D-ERb) were characterized.
E2-induced cell proliferation of cells in which ERb expression was
inhibited was similar to that of the T47D wild-type cells, whereas
this E2-induced cell proliferation was no longer observed when
ERb expression in the T47D-ERb cells was increased. In the
T47D-ERb cell line, DPN also appeared to be able to suppress cell
proliferation when levels of ERb expression were high. In the
T47D-ERb cell line, PPTwas unable to suppress cell proliferation
at all ratios of ERa/ERb expression, reﬂecting its ability to
activate only ERa and not ERb. It is concluded that effects of
estrogen-like compounds on cell proliferation are dependent on
the actual ERa/ERb expression levels in these cells or tissues and
the potential of the estrogen agonists to activate ERa and/or ERb.
Key Words: estrogen receptors; SERM; breast cancer cells;
T47D-ERb; inducible; ER-U2OS-Luc.
Steroid hormones such as estrogens are needed for normal
developmental, physiological, and reproductive processes in
vertebrates (Harris, 2006). Many of these events are modulated
by the activity of estrogen receptor (ER) a and ERb (Pearce and
Jordan, 2004; Pettersson et al., 2000). These two receptors are
encoded by distinct genes and differ in their relative and absolute
tissue distribution (Nilsson et al.,2 0 0 1 ) .I nt h ea b s e n c eo f
estrogen, ERs are sequestered within the nucleus and preserved
in an inactive state by association with heat-shock proteins.
Binding of estrogen or estrogen-like compounds induces
a conformational change in the receptor, an event that promotes
ER homo- or heterodimerization (Matthews and Gustafsson,
2003). Once the ER protein complex is bound to the DNA, it
regulates the expression of estrogen-responsive genes. The ER
homo- and heterodimers activate different signaling pathways
and, therefore, different sets of genes (Acconcia et al., 2004;
Li et al., 2004; Warner and Gustafsson, 2006).
During the last few years, an increasing number of studies
have reported that xenobiotic compounds from different
sources are able to mimic the natural estrogens, thus exerting
comparable effects by activating gene transcription through
ERa and/or ERb (Effenberger et al., 2005; Escande et al.,
2006; Gutendorf and Westendorf, 2001; Sonneveld et al.,
2006; ter Veld et al., 2006; van der Woude et al., 2005).
Estrogens stimulate cell proliferation in normal developing
breast tissues and may prevent osteoporosis by increasing bone
mineral density (Douchi et al., 2007). However, several studies
also suggest that estrogens may stimulate the growth of a large
proportion of ERa-positive breast cancers (Hartman et al.,
2006; Lazennec, 2006; Monroe et al., 2005; Pedram et al.,
2006; Weitzmann and Paciﬁci, 2006). It has been shown that
the ratio of ERa/ERb expression is higher in breast tumors than
in normal tissues due to lower expression of ERb (Lazennec
et al., 2001) and that ERa and ERb are antagonistic to each
other; for example, ERb appears to reduce the cell proliferation
induced by ERa activation, as shown in in vitro cell trans-
fection studies (Bardin et al., 2004; Stossi et al., 2004; Stro ¨m
et al., 2004). Different breast cancer cell lines have been used
for these studies, mainly MCF-7 cells, which all have a high
ERa/ERb ratio (Buterin et al., 2006; Murphy et al., 2005;
Sartippour et al., 2006). It is proposed that differential
responses and tissue-speciﬁc effects induced by food-born
endocrine disrupters, including selective estrogen receptor
modulators (SERMs), might be inﬂuenced by their relative
afﬁnity for the two ERs and the interactive effects of the
estrogen-ER complex with the regulating proteins.
1 To whom correspondence should be addressed. Fax: þ31-317484931.
E-mail: ana.sotoca@wur.nl.
  The Author 2008. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved.
For Permissions, please email: journals.permissions@oxfordjournals.org
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for
non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication
with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For
commercial re-use, please contact journals.permissions@oxfordjournals.orgThe overall objective of the present study was to
quantitatively determine the proliferative/antiproliferative ef-
fect of two model-selective ER agonists in T47D human breast
cancer cells in the presence of increasing amounts of
intracellular ERb. The model compounds studied were pro-
pyl-pyrazole-triol (PPT), a selective ERa agonist, and diary-
lpropionitrile (DPN), a preferential ERb agonist. For
comparison and validation of the different cellular model
systems, estradiol (E2) was included in the studies as well.
The natural ligand E2 is known to stimulate both ERs, with an
approximately 10-fold higher afﬁnity for ERa than for ERb
(Kuiperetal.,1998;Quaedackersetal.,2001).DPNwasreported
to have a 70-fold higher relative binding afﬁnity for ERb than for
ERa, and PPT has a reported 40-fold higher binding afﬁnity for
ERa than for ERb (Helguero et al.,2 0 0 5 ;S u net al., 2003; Wang
et al., 2006). In the present study, the relative isoform-speciﬁc
activityofthethreemodelcompoundswascharacterizedusingthe
humanosteosarcoma(U2OS)reportercelllines,stablytransfected
with ERa or ERb and a luciferase reporter gene with an
33estrogen responsive element (ERE)-TATA-containing mini-
mal promoter region (Quaedackers et al.,2 0 0 1 ) .
In subsequent experiments, the effect of the three compounds
on proliferation of T47D-ERb cells with varying ratios of ERa/
ERb expression was quantiﬁed. In wild-type T47D cells, ERa/
ERb mRNA levels were found to be present in a ratio of 9:1
(Stro ¨m et al., 2004). The T47D-ERb cells are T47D cells stably
transfected with a tetracycline-inducible ERb which allows
studying the inﬂuence of SERMs on cell proliferation in cells
with varying ratio of ERa/ERb expression, by altering expres-
sion of ERb. Inhibition of the expression of the exogenous ERb
is expected to make the T47D-ERb cell line function as a
‘‘pseudo’’-wild-type T47D cell. Since in concurrence with the
expression of ERb, an enhanced green ﬂuorescent protein
(EGFP) from a bidirectional tetracycline-responsive promoter is
coexpressed in the T47D-ERb cells, the levels of ERb expres-
sion can be monitored on the basis of EGFP ﬂuorescence. To
better quantify the relative levels of ERb expression in the
T47D-ERb cells, a method to quantify the EGFP ﬂuorescence in
the cell lysate was developed in the present study.
With the newly developed method to quantify the relative
ERb expression, the effects of E2, DPN, and PPT on the T47D-
ERb cell proliferation were studied at different levels of ERb
expression to determine to what extent the estrogen-induced cell
proliferation depends on the balance between the two major ER
subtypes. In addition, it was investigated whether the effects
observed match those that would have been predicted based on
the U2OS reporter gene test results for these compounds and the
hypothesis that stimulation of ERa activates and of ERb reduces
estrogen-mediated cell proliferation.
MATERIALS AND METHODS
Materials. 17b-Estradiol (E2)(> 98%) and ANTI-FLAG M2 monoclonal
antibody peroxidase conjugate was purchased from Sigma (Zwijndrecht, The
Netherlands). 2,3-Bis(4-hydroxyphenyl)-propionitrile (DPN) and 4,4#,4$-
(4-propyl-[1H]pyrazole-1,3,5-triyl) Tris-phenol (PPT) were purchased from
Tocris Cookson Ltd (Bristol, UK). Dimethyl sulfoxide (DMSO) (> 99%) was
obtained from Acros Organics (Pittsburgh, PA). Tetracycline, streptomycin,
penicillin, and puromycin were acquired from Gibco (Paisley, Scotland). Fetal
calf serum (FCS) (Australian origin, 10099), resazurin, and geneticin were
provided by Invitrogen Life Technologies (Paisley, Scotland). Hyclone
dextran-charcoal–treated FCS (DCC-FCS, #SH30068.05) obtained from Perbio
Science NV (Etten-Leur, The Netherlands) was heat inactivated (30 min at
56 C) followed by two 45-min DCC treatment at 45 C (Horwitz and McGuire,
1978). Phosphate-buffered saline (PBS) (without Ca
2þ and Mg
2þ), nonessential
amino acids (1003, 11140-035), growth medium 1:1 mixture of Ham’s nutrient
mixture F12 and Dulbecco’s modiﬁed Eagle’s medium (DMEM) (31331-038
and 31331-028), phenol red–free exposure medium (21041-025) were supplied
by Gibco. Trypsin 0.25 g/100 ml in PBS was obtained from Difco (Detroit,
MI). Sodium bicarbonate (NaHCO3 > 99.5%), sodium hydroxide (NaOH),
ethylenedinitrotetraacetic acid (EDTA 2H2O; Titriplex), magnesium sulfate
(MgSO4 7H2O), and 1,4-dithiothreitol (DTT) were obtained from Merck
(Darmstadt, Germany). Magnesium carbonate ((MgCO3)4Mg(OH)2 5H2O) was
obtained from Aldrich (St Louis, MO). trans-1,2-Diaminocyclohexane-
N,N,N#,N#-tetraacetic acid monohydrate (CDTA) was obtained from Fluka
(Buchs, Switzerland). Hygromycin and D-luciferin were obtained from Duchefa
(Haarlem, The Netherlands). ATP and the 5-bromo-2#-deoxyuridine (BrdU) kit
(colorimetric, 11647229001) were obtained from Roche Diagnostics (Mannheim,
Germany). BSA Protein Assay Kit was purchased from Pierce (Bonn,
Germany). Tween 20 was obtained from Merck. Sodium dodecyl sulfate
(SDS) was obtained from BDH (Poole, UK). Acrylamide (30% acrylamide/bis
solution 29:1), N,N,N#,N#-tetramethylethylenediamine (TEMED), ammonium
persulfate (APS), and the precision plus dual color protein marker were
obtained from Bio-Rad (Veenendaal, The Netherlands). Milk solution was
provided by Campina (Wageningen, The Netherlands). Nitrocellulose mem-
brane was purchased from Whatman (Amsterdam, The Netherlands). ERb-
speciﬁc primary (Ab288/14C8) and secondary antibody (rabbit anti-mouse) were
providedbyAbcam (Cambridge,MA).Chemiluminescent DetectionECL Kit and
photographic hyperﬁlm were provided by Amersham (Buckinghamshire, UK).
Cell lines. T47D human breast cancer cells were purchased from the
American Type Culture Collection (Manassas, VA). The stably transfected
T47D tetracycline-inducible cell line (T47D-ERb) was made and provided by
Stro ¨m (Stro ¨m et al., 2004). The human osteosarcoma (U2OS) cell lines stably
expressing ERa or ERb, in addition to 33ERE-TATA-luciferase were used as
described before (Quaedackers et al., 2001).
Cell culture conditions. The T47D wild-type cell line was cultured in
a 1:1 mixture of Ham’s nutrient mixture F12 and DMEM (31331-038)
supplemented with 5% FCS. The cells were incubated at 37 C and 5% CO2 in
a humidiﬁed atmosphere. T47D-ERb cells were cultured at the same conditions
but in the presence of 1000 ng/ml tetracycline to fully inhibit ERb expression.
Every 10 passages (about 3 weeks), the cells were reselected with 0.5 lg
puromycin/ml as a selection marker to prevent loss of ERb and EGFP
expression and a concurrent change in phenotype.
ERa- and ERb-U2OS cells were cultured in a 1:1 mixture of DMEM and
F12 (31331-028) buffered with 1260 mg/l NaHCO3, supplemented with 7.5%
Australian FCS, and 0.5% nonessential amino acids. ERa-U2OS-Luc growth
medium was supplemented with geneticin (200 lg/ml) and hygromycin (50 lg/
ml) as selection markers. ERb-U2OS-Luc growth medium was supplemented
with geneticin (200 lg/ml) as selection marker. Cells were cultured at 37 Ca t
7.5% CO2 in a humidiﬁed atmosphere.
Behavior of T47D-wt and T47D-ERb cells during culturing and
exposure. The T47D-wt cells were growing well and nicely attached to the
bottom when cultured in ﬂasks at no more than 85% conﬂuency. Higher cell
densities resulted in cluster formation and reduction of cell size. The T47D-
ERb cells, however, were much more difﬁcult to grow. Especially when ERb
expression was present, the cells often started to round up and detach. This loss
of cell attachment hampered the application of methods to quantify cell
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BrdU method gave good results when compared to protein measurement assay
and cell counting, and we chose to mostly apply the resazurin method as this
method requires less cell handling than the BrdU method.
Exposure conditions for T47D and T47D-ERb cells. Because of
estrogenic activity of phenol red (Glover et al., 1988), experiments were
performed in phenol red–free exposure medium supplemented with 5% DCC-
FCS. Cells were seeded in 96-well plates (100 ll/well; Costar, The Netherlands,
Cambridge,MACat.No.3548)atdensitiesof10
5cells/mlforproliferationand1.8
310
5cells/mlforﬂuorescenceassaysinthepresenceofdifferentconcentrationsof
tetracycline (0–1000 ng/ml) as indicated. The starting percentage of coverage for
ﬂuorescence experiments was higher than for proliferation experiments because
wells had to be fully conﬂuent for optimal sensitivity in the ﬂuorescence
measurements, whereas less conﬂuent wells were needed for proliferation assays.
Plates were incubated overnight at 37 C and 5% CO2. After 24 h, cells were
washed with PBS to remove any trace of tetracycline and exposed to different
concentrations of tetracycline and/or the test compounds as indicated.
Cell proliferation measurements. After 24 h of exposure, proliferation
was determined by measuring BrdU incorporated into DNA following BrdU
Roche’s colorimetric protocol and/or after 96 h of exposure by measuring
mitochondrial activity of viable cells on the basis of chemical reduction of
resazurin to resoruﬁn as previously described (Schriks et al., 2006).
Measurement of incorporated BrdU was performed in a spectrophotometer at
370-nm excitation wavelength and 492-nm emission wavelength, and resoruﬁn
was measured with a ﬂuorometer at an excitation wavelength of 530 nm and
emission wavelength of 590 nm. Other methods for studying cell proliferation
included cell counting and measurement of protein content, the latter by
bicinchoninic acid protein assay.
Measurement of ERb expression–related ﬂuorescence. To quantify ERb
expression–related EGFP ﬂuorescence after 24 h of exposure, medium was
removed from the wells and the cells were washed with 100 ll of diluted PBS
(0.53 PBS in demiwater). To each well, 110 ll of low-salt buffer, consisting of
10mM Tris-HCl, pH 7.8, containing 2mM DTT and 2mM CDTA, was added,
and the cells were allowed to swell while the plates were kept on ice for 20 min.
The plates were then frozen at – 80 C for at least 1 h, and before analysis, they
were thawed on ice and shaken brieﬂy until reaching room temperature. Then,
100-ll aliquots of cell lysates from each well were transferred to a 96-well
transparent plate with rounded bottom (Greiner, Frickenhausen, Germany) to
allow ﬂuorescence measurement in the Millipore Cytoﬂuor 2350 ﬂuorometer.
Excitation was at 485 nm (band width of 20 nm) and emission at 530 nm (band
width of 25 nm).
Protein isolation and SDS-polyacrylamide gel electrophoresis. For the
analysis of the ERb protein expression levels, T47D-ERb cells were grown in
growth medium with 1000 ng/ml of tetracycline in small cell culture ﬂasks until
80–90% conﬂuence. Cells were seeded in exposure medium with tetracycline
for 24 h. Medium was removed, and cells were incubated for 24 h in new
exposure medium with different tetracycline concentrations (0, 10, and 1000
ng/ml of tetracycline). Cells were collected with a scraper and suspended in
PBS. After centrifugation (13,000 3 g, 5 min), PBS was removed and cells
were suspended in lysis buffer supplemented with protease inhibitors. Lysis
was done by three cycles of freezing in – 80 C and thawing. Total protein
content was determined using a bicinchoninic acid protein assay kit and a total
protein amount of 20 lg/lane plus ¼ of 43 sample buffer (8% wt/vol SDS,
40% wt/vol glycerol, 0.2M Tris-HCl, pH 6.8, 0.02% bromophenol blue,
25% vol/vol mercaptoethanol) was loaded onto the gel. Running gel (12%
acrylamide) was prepared by mixing 9.9 ml of deionized water, 12 ml 30%
acrylamide plus 0.8% bisacrylamide, 7.5 ml 1.5M Tris-HCl, pH 8.8, and 300 ll
10% SDS. Polymerization was started by addition of 150 ll 10% APS and
12 ll of TEMED. For the preparation of stacking gel (5% acrylamide), reagents
were mixed in the following proportions: 6.66 ml water, 1.66 ml 30%
acrylamide plus 0.8% bisacrylamide, 1.26 ml 1.5M Tris, pH 8.8, 100 ll 10%
SDS, and 100 ll 10% APS together with 10 ll TEMED. Electrophoresis was
run at 100V for approximately 2 h. After electrophoresis, gels were stained with
Coomassie or used for Western blotting.
Western blotting. Blotting was performed at 100V for 1 h. After the transfer,
unspeciﬁc binding sites on the membrane were blocked with 5% milk solution in
tris-buffered saline (TBS) and 0.05% Tween 20 for 1–2 h. The membrane was
washed in TBS with 0.05% Tween 20 twice for 5 min. For detection of the
exogenousFLAG-ERb, themonoclonalANTI-FLAG M2antibody was diluted in
TBSwith0.05%Tween20.FordetectionofERbinthecontrolT47Dcellline,ERb
mouse monoclonal 14C8 antibody was used. After incubation for 1 h at room
temperaturewithANTI-FLAGM2antibody,themembranewaswashedwithTBS
with 0.05% Tween 20 six times for 5 min each time before electrochemilumi-
nescence (ECL) treatment. Incubation with the 14C8 antibody was performed
overnight at 4 C. After incubation, the membrane was washed with TBS 0.1%
Tween 20 three times for 10 min. Secondary antibodies were diluted 5000 timesin
TBS0.1%Tween20,andincubation was runfor45 minatroom temperature. Rabbit
anti-mouse antibody conjugated with peroxidase was used for ERb. Final washing
steps were done two times with TBS 0.1% Tween and one time with TBS only.
Finally, the membrane was treated with peroxidase substrate (ECL kit) for protein
detection. The reaction was run for 5–7 min, and bands were visualized using
photographic ﬁlm. As a ﬁnal step, membranes were stained with Coomassie blue.
ERa- and ERb-speciﬁc U2OS reporter gene assay. Cultured U2OS cells
were washed with PBS, trypsinized, and seeded in transparent 96-well plates
(Greiner) at 100 ll/well at a density of 10 3 10
4 cells/ml (U2OS-ERa) or 7.5 3
10
4 cells/ml (U2OS-ERb) in a 1:1 mixture of DMEM and Ham’s F12 medium
without phenol red, buffered with 1260 mg/l NaHCO3, and supplemented with
5% DCC-FCS and 0.5% nonessential amino acids. Culture medium was
refreshed after 24 h. Forty-eight hours after seeding, the cells were exposed in
triplicate to E2, DPN, or PPT at the indicated concentrations (ﬁnal DMSO
concentration 0.2%) for 24 h at 37 C and 7.5% CO2 in a humidiﬁed
atmosphere. On each plate, the cells were exposed to different concentrations of
test compounds and calibration points for E2 (EC10,E C 50,E C 100) to be able to
correct for plate to plate variations. After 24 h, the medium was removed, and
cells were washed with 100 ll diluted PBS (0.53 in demiwater) per well. Cells
were lysed with 30 ll of a hypotonic low-salt buffer, consisting of 10mM Tris-
HCl, pH 7.8, containing 2mM DTT and 2mM CDTA. Plates were put on ice for
10 min and subsequently frozen at – 80 C. Before analysis, plates were thawed
on ice for 20 min and shaken brieﬂy until reaching room temperature. Analyses
were performed in a Luminoskan (RS; Labsystems, Helsinki, Finland) at room
temperature as follows: background light emission of each well was measured
for 2 s, then, 100 ll of ﬂashmix was added (20mM tricine buffer, pH 7.8,
supplemented with 1.07mM (MgCO3)4Mg(OH)2 5H2O, 2.67mM MgSO4,
0.1mM EDTA 2H2O, 2mM DTT, 0.47mM D-luciferin, and 5mM ATP), light
emission was immediately measured for 2 s, and extinguished with 50 ll 0.2M
NaOH to prevent cross-talk to the neighboring wells.
Data analysis. Relative light units in every well were corrected for the
corresponding background signal, measured before luciferin addition. The
response of the solvent control was taken as 0% induction. The maximum
induction of luciferase obtained at 30pM E2 for ERa-U2OS cells and at 300pM
E2 for ERb-U2OS cells was set at 100%. The exposure concentration of the
compound at which 50% of the maximum luciferase activity is reached (EC50)
was determined using Slidewrite 6.10 for Windows. The estradiol equivalency
factors (EEF) were calculated as EC50 estradiol/EC50 compound. The concentration
of tetracycline at which 50% of the EGFP ﬂuorescence is inhibited (IC50) was
determined using Slidewrite 6.10 for Windows as well. EGFP ﬂuorescence
reﬂecting the level of ERb induction was expressed relative to the ﬂuorescence
of cells exposed to the solvent control (PBS 0.2%) set at 100%. In addition, in
each experiment, calibration points for E2 were included to be able to correct
for plate to plate variations. The obtained data from proliferation quantiﬁed by
the resazurin method was plotted after subtraction of background signal
(obtained from a well containing all components except for the cells), as
percent proliferation. Results from BrdU were calculated as percentage of
proliferation after background subtraction. The response of cells exposed to the
solvent control (DMSO 0.2%) was set at 100%.
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Characterization of the Selected SERMs
The selectivity of PPT and DPN for ERa and ERb was
studied in the ERa-U2OS-Luc and ERb-U2OS-Luc cells.
Typical dose-response curves for the natural ligand E2 as well
for the SERMs are shown in Figure 1. As previously
demonstrated, E2 showed higher binding afﬁnity for ERa than
for ERb,w i t hE C 50 values of 8 and 65pM, respectively, but E2
is clearly both an ERa and ERb agonist. The ERa-selective
PPT was unable to induce any transcription of the reporter gene
in the ERb-U2OS-Luc cell line, conﬁrming its nature as
a selective ERa modulator. The EC50 for the ERa-dependent
response was 140pM (Fig. 1A) resulting in an EEF compared
to E2 of 0.057, and the maximal induction was 120%. As
expected, DPN showed ERb selectivity with EC50 values of
2 and 59nM for ERb and ERa, respectively. At present, a more
selective ERb agonist could not be identiﬁed, and the ERb
speciﬁcity of DPN in the U2OS cells was at least higher than
that of E2 since the ratios of the EC50 for ERa and the EC50
for ERb activation are, respectively, 0.12 and 29.5 for E2 and
DPN. In the ERa-U2OS cells, DPN did not reach the maximal
E2 induction level, but in the ERb-U2OS, the maximal
induction level of DPN was 110% of the value obtained for
E2 (Fig. 1B). The EEFs for DPN were 1.3 3 10
 4 in the ERa-
U2OS and 0.03 in the ERb-U2OS cells. Table 1 shows an
overview of the EC50, EEF, and maximum effect of PPT and
DPN compared to E2 using the U2OS cell system.
Tetracycline-Dependent Expression of ERb in the T47D-ERb
Cell Line Quantiﬁed by Measuring EGFP Fluorescence
T47D cells were stably transfected with the ERb expression
plasmid under tetracycline-responsive promoter regulation and
with an EGFP gene as a coexpressed reporter also under
regulation of the same tetracycline-responsive promoter. This
allows qualitative/semiquantitative conﬁrmation of ERb ex-
pression by ﬂuorescence microscopy. Maximal levels of
ﬂuorescence were reached after 24 h of cultivation of the cells
in the absence of tetracycline. A simple method for quantitative
measurements of the EGFP as sensitive reporter molecule in
cell lysate of the T47D-ERb was developed. Wells seeded with
high density number of the T47D-ERb cells were exposed to
different concentrations of tetracycline (Fig. 2A). EGFP
ﬂuorescence was measured in the cell lysate. Tetracycline
treatment suppressed EGFP ﬂuorescence in T47D-ERb cells,
with concentrations above 150 ng/ml, resulting in total
ﬂuorescence suppression. Values above 2000 ng/ml of tetra-
cycline not only completely depleted EGFP expression but also
caused cytotoxicity (data not shown). The concentration of
tetracycline at which 50% of the ﬂuorescence, and thus ERb
expression, was inhibited (IC50) was determined to be 9.6 ng/ml
tetracycline. Since the expression of EGFP is linked to the
expression of recombinant ERb, the presence of ERb at protein
level was conﬁrmed using Western blot (Fig. 2B). No
detectable FLAG-ERb protein was expressed in the presence
of 1000 ng tetracycline/ml.
TABLE 1
Overview of the EC50, EEF Values, and Maximum Effect of E2,
PPT, and DPN Tested Using the U2OS Cell System
ERa EC50
Maximum
effect as
% relative
to E2
maximum ERa EEF ERb EC50
Maximum
effect as
% relative
to E2
maximum ERb EEF
E2 8pM 100 1 65pM 100 1
PPT 140pM 120 0.057 — — —
DPN 59nM 73 1.3 3 10
 4 2nM 110 0.03
FIG. 1. ERE-mediated luciferase activity in U2OS-ERa (A) and U2OS-ERb
(B) cells exposed to E2 (d), the ERa-selective PPT (:) and the ERb-selective
DPN (¤). Induction was expressed relative to maximal estradiol response, set at
100%.Data pointsrepresentthemeanof triplicatesexposure± standarddeviation.
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Cells with Inhibited ERb Expression
T47D-wt cells showed a clear E2-dependent increase in cell
proliferation with a maximum of 131% maximal induction of
proliferation at 100pM E2 (Fig. 3). T47D-ERb cells in which
ERb expression was completely inhibited by incubating them
in the presence of 1000 ng tetracycline/ml showed an
E2-dependent cell proliferation that was comparable with the
response obtained in wild-type cells (Fig. 3). The T47D-ERb–
transfected cells with no ERb expression reached the same
maximum proliferation of 131% at 1nM of E2 as the wild-type
cells. In both cell lines, the shape of the dose-response curves
was similar and at concentrations above 1nM E2, cell
proliferation decreased when increasing the concentration of
E2. The dose-response curves for E2-induced proliferation
obtained by measuring BrdU incorporation during the last 4 h
of the 24-h period exposure were comparable to those obtained
when measuring mitochondrial activity during the last 4 h of
96-h exposure using the resazurin method with both cell lines.
Expression of ERb Inhibits E2-Induced Cell Proliferation of
T47D-ERb Cells
Mitochondrial activity of the T47D-ERb cells treated with
1nM E2 and an increasing concentration of tetracycline,
causing decreasing cellular expression levels of ERb, showed
a tetracycline-related increase in proliferation (Fig. 4). In
absence of E2, the cells did not proliferate. The EC50 for
tetracycline-dependent stimulation of E2-mediated cell pro-
liferation was 41 ng tetracycline/ml. At tetracycline concen-
trations lower than 10 ng/ml, where ERb expression levels
were high, no E2-induced proliferation was observed.
FIG. 2. (A) Tetracycline-induced inhibition of ERb expression in T47D-
ERb cells measured via the concurrent expression of EGFP after 24 h of
exposure at 100% cell density. Fluorescence is expressed relative to maximum
expression at 0 ng/ml of tetracycline set at 100%. No ﬂuorescence is observed
above 150 ng of tetracycline/ml. Each data point represents the mean of
triplicate exposure ± SD. (B) T47D-ERb tet-off FLAG-ERb cells were cultured
in the presence (1000 and 10 ng/ml) or absence of tetracycline for 24 h, 14C8
antibody was used to detect ERb in the T47D wild type, and Coomassie
staining was used as loading control. Quantiﬁcation of the intensity of the ERb-
FLAG bands was measured by ImageJ.
FIG. 3. The effect of estradiol (E2) on cell proliferation of T47D-wt and
T47D-ERb cells the latter with maximum inhibition of ERb expression by 1000
ng tetracycline/ml. Cell proliferation after 24 h of exposure is expressed relative
to vehicle control (DMSO) set at 100%. Each data point represents the mean of
triplicates exposure ± SD.
FIG. 4. Cell proliferation of T47D-ERb cells in absence (ﬁlled squares) or
presence (ﬁlled circle) of 1nM E2 at different concentrations of tetracycline.
Exposure was performed during 96 h, and proliferation was quantiﬁed as
mitochondrial activity measured by the resazurin method with ﬂuorescence as
end point. Each data point represents the mean of triplicate exposure ± SD.
EFFECT ERa/ERb ON CELL PROLIFERATION 307Exposure of T47D-ERb (Fig. 5) cells to increasing E2 con-
centrations in combination with 41 ng/ml (EC50) and 1000 ng/ml
of tetracycline resulted in a dose-dependent cell proliferation.
E2-induced proliferation was almost absent in the presence of
0a n d9 . 6n g( I C 50 for ﬂuorescence) tetracycline/ml. Altogether
these data demonstrate the validity of the test system and support
that E2 cannot induce cell proliferation under conditions where
ERb is expressed to relatively higher levels and able to suppress
ERa-mediated induction of cell proliferation.
The Proliferative Effect of Two SERMs
Figure 6 presents the results from experiments in which the
proliferative effect of PPT (Fig. 6A) and DPN (Fig. 6B) was
studied in the T47D-ERb cells at the same four tetracycline
concentration as used in the E2 study (Fig. 4). The straight line
drawn at 164% cell proliferation represents the maximum of
T47D-ERb (ERb absent) and T47D cell proliferation at 1nM of
estradiol.
At 1000 ng/ml of tetracycline, when expression of ERb is
suppressed, PPT was able to induce cell proliferation to a level
of 173%, an induction level that was slightly higher than the
maximal induction of cell proliferation by E2 (164%) under
these conditions. This is in spite of the fact that the afﬁnity of
ERa for PPT was lower than for E2. Although the E2-induced
proliferation with full expression of ERb was reached at 3nM
of PPT (153%), no considerable reduction of proliferation
compared with E2 (124%) was observed under all ERa/ERb
ratios studied due to the inability of PPT to activate ERb.
At the same tetracycline concentration (1000 ng/ml), DPN
induced similar proliferation maximums as E2 (164%)
although at a higher concentration than required for maximal
induction by E2. This can be due to the fact that ERa has
a lower afﬁnity for DPN than for E2. However, DPN appeared
able to suppress cell proliferation when levels of ERb
expression were high. No differences in cell proliferation were
observed between the two lowest tetracycline concentrations (0
and 9.6 ng tetracycline/ml) either for PPT, DPN, or E2.
E2-induced proliferation with full expression of ERb was
lower than proliferation induced with PPT and DPN. The
maximum induced proliferation in the absence of tetracycline
was 153% with 3nM PPT, 128% with 100nM DPN, and 124%
with 1nM E2. In the presence of high levels of ERb, E2- and
DPN-induced proliferation was 40% (from 164% to 124%)
lower compared to the induced proliferation in absence of ERb.
DISCUSSION
Invasion, uncontrolled proliferation, and metastasis are the
most important properties of a malignant cancer. Thus,
proliferation is not the only hallmark of malignant trans-
formation, and proliferation and invasion may under certain
conditions even be contrasting events (Svensson et al., 2003).
In the present study, proliferation was selected as the end point
to characterize the inﬂuence of ERa/ERb ratios and not the
FIG. 5. E2-dependent cell proliferation in the T47D-ERb cells after 96 h of
exposure in combination with 0, 9.6, 41, and 1000 ng tetracycline/ml to inhibit
ERb expression.Eachdatapointrepresentsthemeanof triplicate exposure ±SD.
FIG. 6. The effect of PPT (A) and DPN (B) on T47D-ERb cell proliferation
after96hofexposureincombinationwith0,9.6,41,and1000ngtetracycline/ml,
quantiﬁed as ﬂuorescence using the resazurin method. The line indicates the
proliferation induced by 1nM of E2 when ERb expression was completely
inhibited. Each data point represents the mean of triplicate exposure ± SD.
308 SOTOCA ET AL.invasiveness of the tumor cells since the T47D cell line in
which the variable ERa/ERb ratios can be generated is a non-
or poorly invasive cell line (Adams et al., 2002).
The ratio of ERa/ERb expression in breast tumors is higher
than in normal breast tissues due to a lower expression of ERb.
This has lead to the hypothesis that low levels of ERb may
result in high proliferation rates because of the absence of ERb-
mediated modulation of the proliferative effect of ERa. This
would imply that high levels of ERb stimulation lead to
decreased cell proliferation whereas high levels of ERa
stimulation lead to increased cell proliferation. Therefore, the
objective of the present study was to quantify the differential
effect of a selective ERa and a selective ERb agonist on cell
proliferation of human breast cancer cells with varying but
well-deﬁned ratios of ERa/ERb expression. To this end, the
T47D-ERb cell model was applied in which the levels of the
ERb receptor could be reduced by adding tetracycline. In
addition to the E2-induced cell proliferation under different
levels of ERb expression, also the effect of two pseudo-
estrogens reported to be speciﬁc ERa or ERb agonists was
determined.
Using human osteosarcoma (U2OS) ERa or ERb reporter
cell lines, it could be demonstrated that, compared to E2, PPT
is a selective ERa modulator and DPN a preferential ERb
modulator. In the ERa- and ERb-speciﬁc U2OS-Luc cells, E2
induced ER/ERE–mediated luciferase activity with eight times
higher afﬁnity for ERa than for ERb. DPN was able to induce
luciferase activity through both receptors with a 30 times
higher potency through ERb than ERa. PPT was found to be
a fully ERa-speciﬁc inducer (EEFa ¼ 0.057) while DPN only
reasonably speciﬁcally induced ERb (EEFa ¼ 1.3 3 10
 4,
EEFb ¼ 0.03). This is in accordance with the results previously
reported (Meyers et al., 2001). The fact that PPT was not able
to activate the transcription of the reporter gene in the ERb-
U2OS-Luc is in accordance with earlier observations (Stauffer
et al., 2000). The maximum induction by the partial ERa
agonists DPN did not reach the maximum induction induced by
E2 in the ERa-U2OS system, but DPN induced an even
slightly higher maximum response than E2 in the ERb-U2OS
system.
In normal breast tissues, the ERb to ERa ratio is high and
decreases when breast tumor progresses (Lazennec et al.,
2001). Earlier studies have suggested that when both receptors
are expressed in the cell at the same mRNA levels, E2-induced
proliferation of T47D cells is reduced compared to the E2-
induced proliferation of cells in which only ERa is expressed
(Stro ¨m et al., 2004). Our results in the T47D wild type cells
showed that cells proliferated in the absence of high levels of
ERb and presence of the natural ligand, E2, indicating that
proliferation is E2-ERa mediated. Therefore, to study the role
of ERb in cell proliferation, we used the T47D-ERb cell line
with inducible ERb expression to directly compare the effects
of ERb levels in the same cellular background. As a validation
of the cell system, it could be demonstrated that the complete
inhibition of ERb expression with 1000 ng/ml of tetracycline
resulted in a ‘‘pseudo’’-wild-type T47D cell with similar E2-
induced proliferation responses whereas this E2-induced cell
proliferation was no longer observed when ERb expression in
the T47D-ERb cells was increased. Furthermore, given the fact
that the T47D-ERb cell line is derived from human breast
cancer tissue, the expression levels of ERa and ERb in the cells
when grown in the presence of 1000 ng tetracycline/ml (no
additional ERb expression) can be expected to be physiolog-
ically relevant. Furthermore, previous data reported by Stro ¨m
et al. (2004) revealed that when the cells were grown in the
absence of tetracycline (full ERb expression), the level of ERb,
as judged from mRNA expression levels, appears to be 4-fold
higher than that of ERa. Given the fact that physiological
levels of ERa to ERb may vary in such a way that either one of
the two receptors is dominant (Enmark et al., 1997; Ma ¨kinen
et al., 2001; Pearce and Jordan, 2004), it can be concluded that
the range of ERa to ERb ratios in the T47D-ERb line with
increasing concentrations of tetracycline reﬂects physiologi-
cally relevant variations in the receptor ratio.
The T47D-ERb cell line was engineered to coexpress the
EGFP in concurrence with ERb, which allows indirect
quantiﬁcation of ERb by measuring the ﬂuorescence of EGFP.
In the present study, a simple microtiter plate method was
developed to be able to detect the expression levels of ERb by
measuring in the cell lysate the EGFP ﬂuorescence. The IC50
for the EGFP expression after 24 h of exposure was 9.6 ng
tetracycline/ml (Fig. 2). After 96 h, the EC50 for tetracycline-
mediated stimulation of E2-induced cell proliferation was
41 ng tetracycline/ml (Fig. 4). The difference between the IC50
value for tetracycline-mediated suppression of EFGP and ERb
expression and the EC50 value for tetracycline-mediated
stimulation of E2-mediated cell proliferation reﬂects that for
50% stimulation of E2-mediated cell proliferation, ERb
expression needs to be inhibited by more than 50%.
Our results clearly show an important role of the ERa/ERb
ratio in E2-induced cell proliferation. To better understand the
interaction between ERa and ERb, the quantiﬁcation of the
exact levels of expression of these receptors is crucial. Our
ﬁndings also show that the ER subtype ratio determines the
functional response to SERMs. Our results were consistent
with the hypothesis that ERb opposes ERa proliferative effects
in response to E2. Herein, we show that the proliferative
actions in the T47D-ERb cells were mediated by the ERa,
whereas ERb played an important role in inhibiting the ERa
effectiveness. It cannot yet be concluded whether the inhibition
via ERb results in a reduced transcription of genes involved in
cell division or that possibly nongenomic signal transduction
pathways are induced as well. It has been demonstrated that
ERa/ERb heterodimers and ERa homodimers are preferen-
tially formed in intact cells and heterodimers bind to the ERE
onto the DNA with similar afﬁnity to that of ERa homodimers
and higher afﬁnity than that of ERb homodimers (Cowley
et al., 1997).
EFFECT ERa/ERb ON CELL PROLIFERATION 309The ERa-selective agonist PPT was unable to induce
luciferase activity through ERb (U2OS cells) (Fig. 1B), which
implies that PPT does not activate ERb homodimer-mediated
gene transcription. Moreover, it has been shown that ERa/ERb
heterodimers are only effective in coactivator interaction when
both ERa and ERb are doubly occupied with agonists (Kim
et al., 2005). DPN and PPT are as effective in stimulation of
cell proliferation as E2 in the absence of ERb (Fig. 6). In the
presence of ERb, cell proliferation is decreased. DPN is more
potent than PPT in inhibition of cell proliferation when both
ERa and ERb are present as in contrast to PPT DPN can
activate ERb.
In contrast to exposure to E2 and DPN, exposure to PPT in the
presence of high levels of ERb expression did not give rise to
visible cell death. This corroborates a role of the activated ERb in
the induction of cell death as previously reported (Galluzo and
Marino, 2006; Nomoto et al., 2002). Therefore, it is important to
explain the speciﬁc roles of the ERa and ERb when both
receptors are present and link this to the proliferation outcome.
The current results and developed method show that
activation of ERb can result in a reduction of ERa-mediated
cell proliferation. In the T47D-ERb cell line, PPT was unable
to suppress cell proliferation at all ratios of ERa/ERb
expression, indicating its ability to activate only ERa. Whereas
DPN appeared to be able to suppress cell proliferation when
levels of ERb expression were high since it was able to bind
preferentially to ERb. It is concluded that effects of estrogen-
like compounds on cell proliferation are dependent on the
actual ERa/ERb expression levels in these cells or tissues and
the potential of the estrogen agonists to activate ERa and/
or ERb.
Thus, the use of ERb protein expression levels as a bio-
marker in tumor screening, in addition to protein expression
levels of ERa, has the potential of more successful indication
of therapeutic responses and course/outcome of the disease in
ER-positive tumors. Future studies at a molecular level will be
performed to further elucidate how ERb exerts these effects.
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